Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2021 2
2022 5
2023 3
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T, De Leo A, Coluccelli S, Sanza V, Gruppioni E, Altimari A, Comito F, Melotti B, Marchese PV, Dika E, Venturi F, Corti B, Ciccimarra G, Ciceu CA, Tallini G, de Biase D. Maloberti T, et al. Among authors: marchese pv. Diagnostics (Basel). 2024 Apr 11;14(8):800. doi: 10.3390/diagnostics14080800. Diagnostics (Basel). 2024. PMID: 38667446 Free PMC article.
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.
Dall'Olio FG, Parisi C, Marcolin L, Brocchi S, Caramella C, Conci N, Carpani G, Gelsomino F, Ardizzoni S, Marchese PV, Paccapelo A, Grilli G, Golfieri R, Besse B, Ardizzoni A. Dall'Olio FG, et al. Among authors: marchese pv. Ther Adv Med Oncol. 2022 Feb 12;14:17588359211058391. doi: 10.1177/17588359211058391. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173818 Free PMC article.
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase D, Massari F. Mollica V, et al. Among authors: marchese pv. Pathol Res Pract. 2024 Jan;253:155008. doi: 10.1016/j.prp.2023.155008. Epub 2023 Dec 8. Pathol Res Pract. 2024. PMID: 38103361
Defining high-risk patients: beyond the 8the AJCC melanoma staging system.
Broseghini E, Veronesi G, Gardini A, Venturi F, Scotti B, Vespi L, Marchese PV, Melotti B, Comito F, Corti B, Ferracin M, Dika E. Broseghini E, et al. Among authors: marchese pv. Arch Dermatol Res. 2024 Dec 6;317(1):78. doi: 10.1007/s00403-024-03627-4. Arch Dermatol Res. 2024. PMID: 39643819
16 results